TB-500
Forty-three amino acids. Found in nearly every cell in your body. Most people have never heard of it.
Thymosin Beta-4 — Tβ4 — is a 43-amino acid polypeptide that is endogenous, ubiquitous, and one of the most abundant peptides in mammalian tissue. It is present in nearly every cell type in the body, with particularly high concentrations in platelets, white blood cells, and healing tissue. It was first isolated by Low, Goldstein, and White at the National Cancer Institute in 1981 and has since accumulated one of the largest research bodies of any tissue-repair peptide in the literature.1
In the research peptide market, Tβ4 is most commonly sold under the name TB-500 — a label that requires a brief clarification. TB-500 originally referred to a synthetic heptapeptide fragment corresponding to residues 17–23 of Tβ4 (the sequence LKKTETQ). In practice, most commercial research peptide suppliers — including Elite Biogenix and Atomik Labz — now carry full-length Tβ4 under the TB-500 name. The molecular data on this page and the accompanying card refer to full-length Thymosin Beta-4.
The distinction matters because the two compounds are not interchangeable. Full-length Tβ4 is the complete endogenous protein. The LKKTETQ fragment is the active actin-binding domain — highly bioavailable and stable, but representing only one functional region of a multi-domain molecule. Most of the cardiac, anti-fibrotic, and systemic repair data in the literature is from full-length Tβ4 and its synthetic equivalent, not the isolated fragment.2
What makes Tβ4 mechanistically unusual is that it does not act through a single receptor. Like BPC-157, it operates across multiple downstream systems simultaneously — driven by its core function as an actin-sequestering protein — making it unusually broad in its documented tissue effects.
Actin, migration, and the cellular repair signal your body already knows how to send.
Every cell in your body is built on a scaffold of actin filaments — the cytoskeletal proteins that give cells their structure, allow them to change shape, and enable them to move. When a cell needs to migrate to a wound site, divide, or remodel its internal architecture, it must rapidly reorganize this actin scaffold. Thymosin Beta-4 is the molecule that makes this possible at scale.
Tβ4’s core function is actin sequestration: it binds free G-actin monomers — the building blocks of actin filaments — and holds them in reserve. This prevents uncontrolled actin polymerization while making monomers available for rapid, organized deployment when the cell needs to move or rebuild. It is less a signaling molecule than a cellular supply chain manager.
The LKKTETQ domain and cell migration
The actin-binding activity is concentrated in a seven-amino acid stretch at positions 17–23 of the full protein: the sequence Leu-Lys-Lys-Thr-Glu-Thr-Gln, known as LKKTETQ. This domain binds G-actin with high affinity and is the minimal sequence required to reproduce Tβ4’s cell migration-promoting effects — which is why it became the basis for the TB-500 fragment designation. Research by Philp et al. in FASEB Journal (2003) confirmed this domain as the biologically active region responsible for promoting actin dynamics and keratinocyte migration in wound healing models.3
VEGF upregulation and angiogenesis
Beyond actin regulation, Tβ4 upregulates vascular endothelial growth factor (VEGF) and increases expression of integrin αvβ3 — a key receptor for endothelial cell adhesion during new vessel formation. This angiogenic effect drives blood vessel growth into injured tissue, addressing one of the fundamental bottlenecks in repair: damaged tissue cannot heal without adequate perfusion to deliver oxygen, nutrients, and additional repair signals.4 Tβ4 promotes the formation of new vessels into the wound environment rather than simply dilating existing ones.
Anti-inflammatory and anti-fibrotic signaling
Tβ4 modulates the TGF-β pathway — the central driver of fibroblast activation and pathological collagen deposition. By downregulating TGF-β signaling, it inhibits the conversion of fibroblasts into scar-producing myofibroblasts, reducing the formation of disorganized fibrotic tissue and preserving the structural scaffolding that organized repair requires.5 Separately, Tβ4 has been shown to reduce pro-inflammatory cytokines including TNF-alpha and IL-6 at injury sites, shifting the tissue environment from destructive inflammation toward repair-phase signaling.
Cardiac progenitor cell mobilization
A fourth documented mechanism — and one of the most clinically significant in the Tβ4 literature — is the mobilization of cardiac progenitor cells. Bock-Marquette et al. published in Nature (2004) that Tβ4 activates the survival kinase Akt in cardiac cells and promotes their migration and differentiation into functional cardiomyocytes. A subsequent 2008 study in Circulation Research demonstrated that Tβ4 mobilizes bone marrow-derived progenitor cells and directs their migration to damaged cardiac tissue — the first clear evidence of a systemic repair-recruitment mechanism in a non-cardiac application of the compound.6
The evidence, read honestly.
Tβ4 has one of the larger research bases in this space — published studies span wound healing, cardiac biology, inflammation, and connective tissue across multiple independent research groups. A key caveat applies throughout: the majority of data uses full-length Tβ4, not the TB-500 fragment specifically. No large-scale placebo-controlled human RCT has been completed. Translation from animal models to human clinical outcomes remains the open question across all domains.
| What We Know | Tβ4’s wound healing effects are the most extensively studied in the literature. The LKKTETQ domain promotes keratinocyte migration — the skin cells responsible for re-epithelialization — and has been shown to accelerate wound closure in multiple rodent models including diabetic wound models where healing is significantly impaired.3 Tβ4 promotes organized collagen deposition, reduces wound inflammation, and stimulates angiogenesis into the wound bed simultaneously. A Phase II clinical trial (RegeneRx Biopharmaceuticals) in patients with neurotrophic corneal ulcers showed statistically significant improvement in healing rates versus placebo — one of the few controlled human data points in the Tβ4 literature.7 |
| What We Don’t Know | The corneal ulcer trial is specific to a surface wound application with direct topical administration — not systemic injection. Whether systemic Tβ4 administration produces equivalent wound healing benefits in otherwise healthy adults with normal healing capacity has not been established. The majority of wound healing data is from rodent models with surgically induced injuries, which may not reflect the inflammatory and vascular environment of chronic or age-related wound healing in humans. |
| What That Means | The wound healing evidence base is the strongest in the Tβ4 literature — it is the application with the most mechanistic depth, the most animal data, and the only controlled human trial data. The corneal trial is a meaningful step toward clinical translation. The honest framing for systemic use: the mechanism is well-characterized, the animal data is consistent, and human trial data for systemic administration does not yet exist. |
| What We Know | The cardiac repair literature is where Tβ4’s most compelling — and most discussed — findings live. Bock-Marquette et al. (2004, Nature) demonstrated that Tβ4 activated survival kinase Akt in cardiac progenitor cells and promoted their differentiation into functional cardiomyocytes in a mouse infarction model.6 A 2008 Circulation Research study demonstrated mobilization of bone marrow progenitor cells to damaged cardiac tissue. Separately, multiple studies have documented that Tβ4 downregulates TGF-β signaling in cardiac fibroblasts, reducing collagen deposition and fibrotic scar formation following injury — with one 2015 study reporting reduced collagen content and improved left ventricular function in post-infarction rodents.5 |
| What We Don’t Know | No human cardiac trial for Tβ4 has been completed. The rodent infarction models use surgically induced, acute cardiac injury — a different biological context from the chronic, progressive cardiac remodeling that characterizes age-related heart disease in humans. Whether progenitor cell mobilization observed in rodents translates meaningfully to human cardiac repair, and at what dose and timing, is unknown. RegeneRx’s cardiac program did not advance to Phase III. |
| What That Means | The cardiac data is scientifically significant — published in high-impact journals including Nature and Circulation Research, from multiple independent groups. The anti-fibrotic mechanism via TGF-β inhibition is well-characterized. The absence of human trial data is the honest limitation, and the gap between rodent infarction models and human cardiac disease is substantial. This is an area where the research is compelling and the clinical translation question is genuinely open. |
| What We Know | Tβ4 promotes fibroblast migration and differentiation in tendon and ligament tissue, stimulates organized collagen matrix formation — as opposed to the disorganized scar-like collagen deposited during suboptimal healing — and reduces inflammatory cytokine expression in connective tissue injury models. Studies in rodent tendon and ligament injury models show accelerated functional recovery and improved tensile strength in treated animals.8 Tβ4 is frequently studied alongside BPC-157 as a complementary compound — BPC-157 drives VEGF-mediated blood supply while Tβ4 directs cell migration and structural organization at the repair site. |
| What We Don’t Know | Human musculoskeletal trial data does not exist for Tβ4. Whether the organized collagen remodeling seen in rodent tendons translates to human tendon and ligament repair — across the very different loading, vascularization, and tissue density of human connective tissue — is unknown. Optimal dosing, timing relative to injury, and administration route for musculoskeletal applications have not been established in humans. |
| What That Means | The connective tissue evidence is mechanistically coherent and directionally consistent in animal models. The synergy with BPC-157 — documented in the research literature — is one reason these two compounds are studied together. The honest position: strong animal evidence, plausible mechanism, no human trial data for this application. |
| What We Know | Tβ4 crosses the blood-brain barrier and has been shown to promote oligodendrocyte differentiation and remyelination in rodent models of CNS injury and demyelinating disease — a finding that has attracted significant research interest given the limited options for myelin repair.9 Anti-inflammatory effects are consistently documented across tissue types: Tβ4 reduces TNF-alpha, IL-1β, and IL-6 in injury models and modulates the NF-κB pathway, one of the central regulators of inflammatory gene expression. These effects have been documented independently of the actin-sequestration mechanism, suggesting multiple anti-inflammatory pathways. |
| What We Don’t Know | The neurological findings are preliminary and primarily from rodent models of acute CNS injury — not the chronic, progressive neurodegeneration that characterizes most human neurological disease. Whether remyelination effects observed in animal models translate to human demyelinating conditions has not been tested. The systemic anti-inflammatory effects, while consistently observed, have not been characterized in controlled human trials. |
| What That Means | The anti-inflammatory and neurological findings are among the more interesting areas of the Tβ4 literature — particularly the remyelination data, which is mechanistically distinct from most repair peptides. These are genuinely early-stage findings that warrant monitoring as research develops. They do not constitute evidence for treating neurological conditions in humans. |
Forty-three amino acids. Found in nearly every cell in your body. Most people have never heard of it.
Thymosin Beta-4 — Tβ4 — is a 43-amino acid polypeptide that is endogenous, ubiquitous, and one of the most abundant peptides in mammalian tissue. It is present in nearly every cell type in the body, with particularly high concentrations in platelets, white blood cells, and healing tissue. It was first isolated by Low, Goldstein, and White at the National Cancer Institute in 1981 and has since accumulated one of the largest research bodies of any tissue-repair peptide in the literature.1
In the research peptide market, Tβ4 is most commonly sold under the name TB-500 — a label that requires a brief clarification. TB-500 originally referred to a synthetic heptapeptide fragment corresponding to residues 17–23 of Tβ4 (the sequence LKKTETQ). In practice, most commercial research peptide suppliers — including Elite Biogenix and Atomik Labz — now carry full-length Tβ4 under the TB-500 name. The molecular data on this page and the accompanying card refer to full-length Thymosin Beta-4.
The distinction matters because the two compounds are not interchangeable. Full-length Tβ4 is the complete endogenous protein. The LKKTETQ fragment is the active actin-binding domain — highly bioavailable and stable, but representing only one functional region of a multi-domain molecule. Most of the cardiac, anti-fibrotic, and systemic repair data in the literature is from full-length Tβ4 and its synthetic equivalent, not the isolated fragment.2
What makes Tβ4 mechanistically unusual is that it does not act through a single receptor. Like BPC-157, it operates across multiple downstream systems simultaneously — driven by its core function as an actin-sequestering protein — making it unusually broad in its documented tissue effects.
Actin, migration, and the cellular repair signal your body already knows how to send.
Every cell in your body is built on a scaffold of actin filaments — the cytoskeletal proteins that give cells their structure, allow them to change shape, and enable them to move. When a cell needs to migrate to a wound site, divide, or remodel its internal architecture, it must rapidly reorganize this actin scaffold. Thymosin Beta-4 is the molecule that makes this possible at scale.
Tβ4’s core function is actin sequestration: it binds free G-actin monomers — the building blocks of actin filaments — and holds them in reserve. This prevents uncontrolled actin polymerization while making monomers available for rapid, organized deployment when the cell needs to move or rebuild. It is less a signaling molecule than a cellular supply chain manager.
The LKKTETQ domain and cell migration
The actin-binding activity is concentrated in a seven-amino acid stretch at positions 17–23 of the full protein: the sequence Leu-Lys-Lys-Thr-Glu-Thr-Gln, known as LKKTETQ. This domain binds G-actin with high affinity and is the minimal sequence required to reproduce Tβ4’s cell migration-promoting effects — which is why it became the basis for the TB-500 fragment designation. Research by Philp et al. in FASEB Journal (2003) confirmed this domain as the biologically active region responsible for promoting actin dynamics and keratinocyte migration in wound healing models.3
VEGF upregulation and angiogenesis
Beyond actin regulation, Tβ4 upregulates vascular endothelial growth factor (VEGF) and increases expression of integrin αvβ3 — a key receptor for endothelial cell adhesion during new vessel formation. This angiogenic effect drives blood vessel growth into injured tissue, addressing one of the fundamental bottlenecks in repair: damaged tissue cannot heal without adequate perfusion to deliver oxygen, nutrients, and additional repair signals.4 Tβ4 promotes the formation of new vessels into the wound environment rather than simply dilating existing ones.
Anti-inflammatory and anti-fibrotic signaling
Tβ4 modulates the TGF-β pathway — the central driver of fibroblast activation and pathological collagen deposition. By downregulating TGF-β signaling, it inhibits the conversion of fibroblasts into scar-producing myofibroblasts, reducing the formation of disorganized fibrotic tissue and preserving the structural scaffolding that organized repair requires.5 Separately, Tβ4 has been shown to reduce pro-inflammatory cytokines including TNF-alpha and IL-6 at injury sites, shifting the tissue environment from destructive inflammation toward repair-phase signaling.
Cardiac progenitor cell mobilization
A fourth documented mechanism — and one of the most clinically significant in the Tβ4 literature — is the mobilization of cardiac progenitor cells. Bock-Marquette et al. published in Nature (2004) that Tβ4 activates the survival kinase Akt in cardiac cells and promotes their migration and differentiation into functional cardiomyocytes. A subsequent 2008 study in Circulation Research demonstrated that Tβ4 mobilizes bone marrow-derived progenitor cells and directs their migration to damaged cardiac tissue — the first clear evidence of a systemic repair-recruitment mechanism in a non-cardiac application of the compound.6
The evidence, read honestly.
Tβ4 has one of the larger research bases in this space — published studies span wound healing, cardiac biology, inflammation, and connective tissue across multiple independent research groups. A key caveat applies throughout: the majority of data uses full-length Tβ4, not the TB-500 fragment specifically. No large-scale placebo-controlled human RCT has been completed. Translation from animal models to human clinical outcomes remains the open question across all domains.
Your body already makes this. After 40, it makes less of it — and needs more of what it does.
Tβ4 expression is not static across a lifetime. Research suggests that endogenous Tβ4 levels decline with age — and that the repair environments in which it operates become progressively less responsive to its signals. The combination of reduced Tβ4 availability and declining fibroblast sensitivity, reduced VEGF responsiveness, and chronic low-grade inflammation means that the actin-mediated repair cascade Tβ4 initiates is operating under increasingly compromised conditions in midlife tissue.
For women specifically, the perimenopausal and postmenopausal transition adds hormonal disruption to this baseline. Estrogen plays a documented role in skin collagen maintenance, wound healing speed, and fibroblast activity. As levels decline, the tissue repair environment — already under pressure from age-related changes — becomes less efficient across multiple systems simultaneously: skin, connective tissue, cardiovascular, and immune.
Tβ4’s research profile maps directly onto several of these declining systems. Its actin-mediated cell migration mechanism drives repair signals to wherever they are needed. Its anti-fibrotic TGF-β modulation counters the tendency toward pathological scarring rather than functional repair that increases with age. Whether exogenous Tβ4 administration meaningfully restores these declining repair capacities in perimenopausal and postmenopausal women is a research question without a definitive human trial answer. The mechanistic rationale is sound. The clinical evidence is not yet there.
TB-500 is frequently discussed alongside BPC-157 as a complementary repair compound — the two operate through different mechanisms but converge on the same outcome: better-resourced, better-organized tissue repair. For the full account of the biology of recovery after 40, see The Science of Recovery and the Female Body. For the BPC-157 compound profile, see BPC-157 — What the Research Actually Shows.